Q2 2026 Uniqure NV Earnings Call Transcript
Key Points
- uniQure NV (QURE) received guidance from both the FDA and MHRA, advancing regulatory pathways for AMT-130.
- Promising early data from Fabry disease and refractory temporal lobe epilepsy programs were announced.
- The company strengthened its balance sheet into 2030 through a follow-on offering.
- uniQure NV (QURE) is on track to submit a BLA for AMT-130 under the accelerated approval pathway.
- The company has engaged deeply with Huntington's Disease Centers of Excellence, payers, and the patient community to prepare for potential commercialization.
- Research and development expenses remain high, with $34 million reported for the quarter.
- There is a need to align the confirmatory study design with the FDA, which could impact timelines.
- The FDA requires the confirmatory study to be well underway at the time of accelerated approval, posing operational challenges.
- AMT191 for Fabry disease faced dose-limiting toxicity issues, leading to a pause in additional dosing.
- Selling, general, and administrative expenses increased significantly, driven by higher employee-related costs.
Hello, and thank you for standing by. My name is Joy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Unicure second quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise.
After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. We kindly ask that you please limit your questions to one and one follow-up.
Thank you. I would now like to turn the call over to Kiara Russo, Senior Director of Investor Relations. Please go ahead, ma'am.
Good morning, and thank you for joining us for Unicure's second quarter of 2026 earnings call.
Earlier this morning, Unicure released financial results second quarter of 2026, and our press release is available on the Investors and Media section of our website at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
